Novatend’s cutting-edge tissue engineering platform provides a full suite of bone grafting and biomaterial solutions designed to meet your surgical needs.
Learn About Us...
In proud partnership with
Our OEM and contract manufacturing partner and owner of the intellectual property behind the Osteogenic Bone Matrix that powers our devices developed by Dr Nicolaas Duneas (PhD, MBA).
Get Started
NEXT-GENENRATION
TISSUE-ENGINEERING
Novatend uses its knowledge of tissue engineering and medical device manufacturing to provide the most affordable high-quality biomaterial grafting solutions in the world using our proprietary technology platform.
LEARN MORE
MOST POPULAR DEVICES
All devices are high-quality locally manufactured grafts that yield predictable and reliable clinical outcomes.
NovaDBMX
Ready-to-inject osteoinductive putty containing high levels of BMP-complex for spinal fusions, ORIFS and non-unions
NovaGROW
DBM Granules with standardized BMP levels for sinus lifts, ridge augmentations and socket preservations
NovaMEM
Atelocollagen barrier membrane for graft sequestration/tissue approximation
NovaGRAFT
Biocompatible spongiosa for reconstructive procedures
NovatendX
Bioresorbable rotator cuff patch graft for the augmentation of traditional repairs
NovaSGX
Fully synthetic ready-to-inject graft for maxillofacial and periodontal procedures
NEXT-GEN INJECTABLE
BONE GRAFTING
We provide the latest in bone grafting materials straight to our customers. This enables shorter time spent in theater, reduced risk due to disease-transfer and infection and for a fraction of the price of a second procedure
Get Started
We have built a great platform in which we can provide cutting edge regenerative medicine based solutions directly to distributors, hospital groups and surgeons. Our devices sell at a fraction of the cost of imported competitors and are fully reimbursed by major medical aid groups giving patients a much needed break from inflated out-of-pocket expenses.
- MC Labuschagne, Executive Director
11.7%
Month on Month Growth
0
Adverse Events Reported